Pds biotech announces release of abstract for pds0101 in nci-led phase 2 clinical study for oral presentation at 2021 asco meeting

Objective responses (tumor reduction) observed in 83% (5 of 6) of hpv16-positive relapsed or refractory checkpoint inhibitor naÏve patients and 63% (5 of 8) of hpv16-positive relapsed or refractory advanced cancer patients who have also failed checkpoint inhibitor therapy objective responses (tumor reduction) observed in 83% (5 of 6) of hpv16-positive relapsed or refractory checkpoint inhibitor naÏve patients and 63% (5 of 8) of hpv16-positive relapsed or refractory advanced cancer patients who have also failed checkpoint inhibitor therapy
PDSB Ratings Summary
PDSB Quant Ranking